Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 1/20 | 0.40 |
| ▸ | FNTB | P49356 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | DGKG | P49619 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308854 | 0.86 | FNTA (0.48) | FNTAFNTBCHRM2CHRM3CHRM4 | |
| SCHEMBL2311931 | 0.83 | OPRM1 (0.42) | CHRM2CHRM3CHRM4CHRM1MAPT | |
| SCHEMBL2311074 | 0.82 | RAB9A (0.46) | CHRM4MAPT | |
| SCHEMBL2314289 | 0.80 | CACNA2D1 (0.55) | NPSR1MEN1KMT2A | |
| SCHEMBL2307819 | 0.80 | OPRM1 (0.51) | DRD2DRD4CHRM2CHRM3CHRM4 | |
| SCHEMBL2306085 | 0.80 | OPRM1 (0.51) | DRD2DRD4CHRM2CHRM3CHRM4 | |
| SCHEMBL2380341 | 0.79 | ALDH1A1 (0.40) | CHRM2CHRM3CHRM4CHRM1MEN1 | |
| SCHEMBL2308063 | 0.78 | OPRM1 (0.47) | CHRM2CHRM3CHRM4CHRM1MAPT | |
| SCHEMBL2381415 | 0.78 | NPC1L1 (0.45) | CHRM2CHRM3CHRM4CHRM1MEN1 | |
| SCHEMBL2312090 | 0.78 | CACNA2D1 (0.55) | DRD2NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | claimed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | claimed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | claimed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | FNTA 4435/4885FNTB 3659/4885DRD2 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.